CN1183912C - Medicine for relieving itching and detumescence - Google Patents
Medicine for relieving itching and detumescence Download PDFInfo
- Publication number
- CN1183912C CN1183912C CN 00130429 CN00130429A CN1183912C CN 1183912 C CN1183912 C CN 1183912C CN 00130429 CN00130429 CN 00130429 CN 00130429 A CN00130429 A CN 00130429A CN 1183912 C CN1183912 C CN 1183912C
- Authority
- CN
- China
- Prior art keywords
- medicine
- detumescence
- antipruritic
- effect
- tannic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention discloses a new medicine with the functions of itch relief and detumescence. The medicine is composed of methylene blue and tannic acid and can be prepared into various preparations; the medicine has the functions of the itch relief and the detumescence to pruritus and redness, particularly pruritus and redness symptoms caused by the bites of mosquitoes, midges and fleas, and the therapeutic effect is notable.
Description
Technical field
The present invention relates to a kind of antipruritic, detumescence medicine, a kind of specifically symptoms such as the pruritus that caused, redness that insects such as mosquito, midge, flea are bitten have medicine antipruritic, the detumescence effect.Behind mosquito, midge, the flea bite human body skin, symptoms such as pruritus, redness can appear in the affected part, have seriously disturbed people's orthobiosis.According to Ministry of Public Health unified editing higher medical universities and colleges' teaching materials " skin cypridology " (third edition, 1996 publish) record, the generation of these symptoms is mainly by 4 kinds of approach: 1, bite mechanical damage in the process.2, the toxicity of the secretions of insect, Excreta, venom etc. stimulates.3, the anaphylactic type that causes of poison gland leachate of insect and antigenic substance that saliva contains.4, the mouthpart of insecticide is left over the foreign body reaction that causes in vivo.Symptoms such as redness, pruritus mainly by the 2nd, the 3rd kind of reason cause.
Background technology
At present, biting the pruritus, the redness that are caused at mosquito, midge, flea etc. does not still have than good method, and symptom the lighter will not treat substantially, and heavier person can give following a few class Drug therapy:
1. nice and cool class medicine.This class medicine is to be the various kinds of drug that substrate is made with the Mentholum, is used for antipruritic by feeling nice and cool.For example menthocamphorate, essential balm.It is the most extensive that this class clinical drug uses, but antipruritic, the detumescence curative effect is relatively poor.Various kinds of drug is used for antipruritic by feeling nice and cool.For example menthocamphorate, essential balm.It is the most extensive that this class clinical drug uses, but antipruritic, the detumescence curative effect is relatively poor.
2. alkalescent medicine.By in and the polypide acid venom of discharging come relief of symptoms.Be mainly the ammonia preparation.Because of it has than penetrating odor and remission are not obvious greatly, now substantially need not.
3. anaesthetize the class medicine.Representing medicine is lignocaine, procaine.This class medicine is anaesthetized teleneuron by modes such as local anaesthesia, sealings, plays itching-relieving action.Its shortcoming is that action time is short, uses inconvenience, and misery is arranged.
4. antihistaminic.This class medicine is gone up H by suppressing histamine and effector lymphocyte
1The combination of receptor, thus the allergy that it causes suppressed, reach antipruritic, detumescence effect.Represent medicine that diphenhydramine, promethazine are arranged.It is bigger in whole body, no specificity, side effect that its shortcoming is a drug effect.Only the critical patient is used.
5. corticosteroid hormone.This class medicine has antiinflammatory, suppresses immunoreation, effects such as antitoxin.Shortcoming is that specificity is low, and side effect is big, is only applicable to the critical patient.
6. Chinese medicine.The traditional Chinese medical science thinks that this kind pruritus, the red and swollen ailment said due to cold or exposure that belongs to invade due to the skin, and the medicines that dispel the wind that adopt give the compound preparation fumigation and wash method that medicines such as Herba Schizonepetae, Radix Saposhnikoviae, Radix Sophorae Flavescentis, the Fructus Kochiae, Folium Artemisiae Argyi, the Radix Stemonae are formed more in the treatment, and its shortcoming is to use inconvenience, weak curative effect.The object of the present invention is to provide a kind of antipruritic, detumescence effect that has, can play therapeutical effect pruritus, the redness that mosquito, midge, flea etc. bite generation, and rapid-action, easy to use medicine.
Summary of the invention
Solution of the present invention is based on the understanding of modern medicine to pruritus, red and swollen mechanism of production, the toxicity that is primarily aimed at insect secretions, Excreta, venom etc. stimulates, and the process of the anaphylactic type that causes of the antigenic substance that contains of poison gland leachate and saliva.Become to be grouped into for two kinds by serge blue and tannic acid, by antipruritic, the repercussive effect of approach performance of block nerves tip sensory function and precipitation allergic protein.
The present invention is made by following component dry powder: (consumption is a weight portion)
Serge blue 1-200 part tannic acid 20-200 part
The formula optimization weight proportion scope of preparation medicine of the present invention is:
Serge blue 1-20 part tannic acid 20-100 part
Pharmaceutical formulation optimum weight proportioning of the present invention is:
20 parts of 2 parts of tannic acids of serge blue
Most preferred dosage form of the present invention is for making the mixture of solvent with water.
The dry powder blend of above-mentioned arbitrary component can be obtained this medicine after evenly.Materials such as this medicine is water-soluble, ethanol, glycerol.This medicine can add the solvent of arbitrary umber, directly acts on the part of pruritus, redness.
An important feature of the present invention is a serge blue with after tannic acid mixes, and it is antipruritic, the detumescence effect plays joint action of potentiation, obviously is better than using separately serge blue and tannic acid preparation.Serge blue and tannic acid have certain antipruritic, detumescence effect respectively, but use is wherein a kind of separately, and clinical efficacy is relatively poor, does not reach therapeutic effect, so do not use these two kinds of medicines to come antipruritic, detumescence in clinical substantially.
Medical research confirms that skin has the certain absorption effect, when skin bitten swelling appears and after, permeability strengthens, its Absorption can strengthen 2-6 doubly, is suitable for the affected part topical.
Serge blue is mainly used in cyanide and nitrite poisoning at present as a kind of reductant-oxidant.In recent years studies confirm that serge blue can act on teleneuron, cause the damage of nerve marrow reversibility, scratchiness is temporarily disappeared.Its redox also can destroy antigenic substance, weakens the allergy effect.Tannic acid turns usefulness into by tanning, can precipitating proteins, and react with alkaloid and detoxify.After absorbing the affected part, can make the antigenic substance degeneration, suppress allergy, the astriction that itself has energy vasoconstrictive disappears redness.Serge blue can enter affected part (the swelling position after biting) by skin absorbs rapidly with after tannic acid mixes, and plays significantly antipruritic, detumescence effect.
Another important feature of the present invention is that serge blue and tannic acid chemical property are stable, and the two after mixing chemical reaction does not take place, does not produce novel substance, avirulence.On this basis, can be made into various dosage forms such as mixture, tincture, unguentum.Especially with mixture curative effect the best.This medicine can add essence or some other chemical substance and antipruritic, detumescence effect does not go down.This medicine is under some Reducing agent effect (adding zinc powder as dilute sulfuric acid), and its blueness can temporarily disappear and take off, but does not influence its curative effect.
The 3rd characteristics of the present invention are that serge blue mixes its antipruritic, collaborative reinforcement of detumescence effect of back with tannic acid, and its effect becomes positive correlation with the content of this medicine in various dosage forms.
The specific embodiment
The present invention shows that through clinical use result following advantage is arranged:
This drug effect time fast, be coated with and put in affected part several seconds to one minute most patients affected part pruritus transference cure on the skin.Red and swollen basic the disappearance leaves no trace in 2-12 hour.
2. this pharmaceutical physicochemistry stable in properties can long-term storage in closed environment.Can stable existence in various solvents.
3. this medicine can add other material, makes new preparation, as long as tannic acid, the composition of serge blue own are not destroyed, it is antipruritic, the detumescence effect is constant substantially.
4. after this Drug therapy, every function of illing skin (comprising the pain sensation, sense of touch, thermo aesthesia) can be recovered fully, does not stay any sequela.
5. this pharmaceutical properties is stable, and is safe in utilization, has no side effect.For example blue-black ink promptly is the mixed liquor that contains serge blue and tannic acid.Serge blue and tannic acid extensively are present in each kind of plant, the mineral, are extensive use of no obvious adverse reaction as medicine and food composition (containing tannic acid in the routine Folium Camelliae sinensis) in clinical.Serge blue intravenous injection 500mg is still safe in utilization according to reports.
6. this medicine can be made into various dosage forms, and is clinical easy to use.
Claims (5)
1. one kind has medicine antipruritic, the detumescence effect, it is characterized in that it is the medicament of being made by the following weight proportion raw material:
Serge blue 1-200 part, tannic acid 20-200 part.
2. according to claim 1 have a medicine antipruritic, the detumescence effect, and wherein the weight proportion of each raw material is:
Serge blue 1-20 part, tannic acid 20-100 part.
3. according to claim 1 have a medicine antipruritic, the detumescence effect, and wherein the weight proportion of each raw material is:
2 parts of serge blues, 20 parts of tannic acids.
4. describedly have a medicine antipruritic, the detumescence effect according to claim 1,2 or 3, it is characterized in that described medicament is the above the dosage form that is used for topical of any pharmaceutics.
5. according to claim 4 have a medicine antipruritic, the detumescence effect, it is characterized in that said medicament is mixture, unguentum, tincture.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 00130429 CN1183912C (en) | 2000-09-26 | 2000-09-26 | Medicine for relieving itching and detumescence |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 00130429 CN1183912C (en) | 2000-09-26 | 2000-09-26 | Medicine for relieving itching and detumescence |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1345586A CN1345586A (en) | 2002-04-24 |
| CN1183912C true CN1183912C (en) | 2005-01-12 |
Family
ID=4594179
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 00130429 Expired - Fee Related CN1183912C (en) | 2000-09-26 | 2000-09-26 | Medicine for relieving itching and detumescence |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1183912C (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108025020A (en) * | 2015-09-10 | 2018-05-11 | 来乐研究所有限公司 | Antipruritic |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102824359A (en) * | 2011-06-17 | 2012-12-19 | 张廷兴 | Mosquito-toxin-removing liniment |
| CN110840902A (en) * | 2019-12-05 | 2020-02-28 | 河北医科大学 | Application of tannic acid in preparing medicine for inhibiting pruritus |
| CN115633691B (en) * | 2022-10-12 | 2024-03-29 | 大连国际旅行卫生保健中心(大连海关口岸门诊部) | Use of tannins as mosquito attractant components |
-
2000
- 2000-09-26 CN CN 00130429 patent/CN1183912C/en not_active Expired - Fee Related
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108025020A (en) * | 2015-09-10 | 2018-05-11 | 来乐研究所有限公司 | Antipruritic |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1345586A (en) | 2002-04-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69832055T2 (en) | TRANSDERMAL DELIVERY SYSTEM | |
| US5162037A (en) | Magnetically influenced homeopathic pharmaceutical formulations, methods of their preparation and methods of their administration | |
| Mostofa et al. | Antidiabetic effects of Catharanthus roseus, Azadirachta indica, Allium sativum and glimepride in experimentally diabetic induced rat | |
| CN109125107B (en) | Polypeptide composition for effectively improving and repairing facial hormone-dependent dermatitis | |
| US20030157185A1 (en) | Topical treatment of neuropathy | |
| WO2009114087A2 (en) | A method for treating pruritus by administering fullerenes | |
| US7871647B1 (en) | Topical treatment of neuropathy | |
| CN1183912C (en) | Medicine for relieving itching and detumescence | |
| CN1084765A (en) | Stasis eliminating bone joint medicine | |
| CN101669986A (en) | Compound gel preparation containing sophora alopecuroide oil | |
| CN1876034A (en) | An externally applied analgetic and preparation method thereof | |
| AU632481B2 (en) | Magnetically influenced homeopathic pharmaceutical formulations, methods of their preparation and methods of their administration | |
| CN1565462A (en) | Itch relieving detumescent medicine | |
| CN112521389B (en) | Medicament and method for promoting wound healing | |
| CN1052423C (en) | Medicine for treatment of uroschesis | |
| CN1047080C (en) | Process for preparing medicine to inhibit skin itch | |
| CN1899520A (en) | Chinese medicine composition for removing wart nevus | |
| CN1047079C (en) | Process for preparing tinea medicine | |
| CN1814004A (en) | Medicine for treating skin inflammation | |
| CN1163241C (en) | Compound Tournefortia monrana granules preparation and preparation thereof process | |
| CN1084748A (en) | Quick results arthritis dressing and manufacture method thereof | |
| CN106074995A (en) | A kind of bactericidal composition for treating female sex organs inflammation and application thereof | |
| CN1077893A (en) | Preparation method of Dantian heart-strengthening plaster | |
| CN105641094A (en) | Composition for treating children dermatitis and preparation method thereof | |
| CN1186670A (en) | Xinwu dermatitis liquid and its preparing method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C06 | Publication | ||
| PB01 | Publication | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20050112 Termination date: 20091026 |